Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06577987

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients With Advanced Solid Tumor Malignancies

Sponsor: Circle Pharma

Conditions Advanced Solid Tumor Breast Neoplasms Cancer Lung Cancer Metastatic Solid Tumor Neuroendocrine Carcinoma Neuroendocrine Tumors RB1 Gene Mutation Refractory Solid Tumor Triple Negative Breast Cancer

Interventions CID-078 Monotherapy

Updated 5 times since 2024 Last updated: Sep 9, 2025 Started: Aug 14, 2024 Primary completion: Jan 14, 2027 Completion: Mar 14, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Solid Tumor and Breast Neoplasms, this trial is actively recruiting participants. The trial is conducted by Circle Pharma and has accumulated 5 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE1
Jun 2025 — Oct 2025 [monthly]

Recruiting PHASE1
Apr 2025 — Jun 2025 [monthly]

Recruiting PHASE1
Jan 2025 — Apr 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE1

First recorded

Aug 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Circle Pharma

Data source: Circle Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials